Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, Larson MC, Maurer MJ, Slager S, Macon WR, King RL, Feldman AL, Gandhi AK, Link BK, Habermann TM, Yang ZZ, Ansell SM, Cerhan JR, Witzig TE, Nowakowski GS, Novak AJ.
Hartert KT, et al. Among authors: manske m.
Leukemia. 2021 Feb;35(2):522-533. doi: 10.1038/s41375-020-0766-4. Epub 2020 Mar 5.
Leukemia. 2021.
PMID: 32139889
Free PMC article.
Clinical Trial.